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ABSTRACT 
Intravaginal drug delivery can elicit a local effect, or deliver drugs systemically without hepatic first 
pass metabolism. There are a number of emerging areas in intravaginal drug delivery, but the vagina 
is a challenging route of administration, due to the clearance mechanisms present which result in poor 
retention of dosage forms, and the potential for irritation and other adverse reactions. Gel 
formulations are desirable due to the ease of application, spreading and that they cause little to no 
discomfort to the patient. However, these dosage forms, in particular, are poorly retained and 
traditional gels typically have little control over drug release rates. This has led to a large number of 
studies on improving the retention of vaginal gels and modulating the controlled release of drugs from 
the gel matrix.  
This review outlines the anatomy and physiology of the vagina, focussing on areas relevant to drug 
delivery. Medical applications of vaginally administered medicines is then discussed, followed by an 
overview of polymeric gels in intravaginal drug delivery. The sensorial properties of intravaginal gels, 
and how these relate to user compliance are also summarised. Finally, some important barriers to 
marketing approval are described.  
  
1. INTRODUCTION 
Intravaginal administration involves the application of a substance into the body of the vagina, often 
via an applicator. The main advantage of this route of administration is that diseases and conditions 
of the vagina may be treated locally, providing a high concentration of drug at the site of disease and 
potentially limiting any adverse effects away from this region [1]. There are numerous diseases and 
conditions for which it is necessary to administer a drug intravaginally, as well as prophylactic and 
fertility-promoting applications, and several drug delivery devices are currently in use, including 
vaginal gels, pessaries, and intravaginal rings. This review will firstly discuss the anatomy of the vagina, 
followed by a description of applications of intravaginal medicines, a review of polymeric gels intended 
for intravaginal drug delivery, and a discussion of barriers to approval. There are several reviews 
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concerning other dosage forms, such as vaginal rings and nanoparticles [1–7], or those that focus on 
specific applications or disease states [2,8,9].  This review is intended as a broader overview of gels in 
intravaginal drug delivery and discussion of the translation of such formulations into approved 
medicines. 
 
2.  THE VAGINA – FEATURES RELEVANT TO DRUG DELIVERY. 
2.1.  ANATOMY AND PERMEABILITY OF THE VAGINA 
The female reproductive tract (Figure 1) consists of the ‘upper female reproductive tract’, made up of 
ovaries, fallopian tubes, and the uterus, and the ‘lower female reproductive tract’, which includes the 
vagina, ectocervix, and external genitalia. The cervix is a narrowing portion of the uterus ending at the 
vagina in a conical bulge known as the ectocervix. The mucosal lining of the uterus is called the 
‘endometrium,’ and the mucosa of the cervix is more specifically the ‘endocervix’ [10]. The 
endometrium sits within the myometrium, which consists mainly of smooth muscle cells. The upper 
female reproductive tract is lined  with a layer of columnar epithelium possessing tight junctions [10]. 
The cervix is further coated with mucus, secreted by epithelial cells on the endocervical glands [11]. 
The thickness of the mucus layer and mucus consistency is dependent on the phase of the menstrual 
cycle [11]. 
  
Figure 1: A schematic diagram of the female reproductive tract. 
The ‘lower’ female reproductive tract consists of the ectocervix and vagina. The vagina is a muscular 
tube that extends from the ectocervix of the uterus to the vaginal opening, and sits between the 
urethra and rectum. The lining, or ‘mucosa’, of the vagina consists of a non-keratinising stratified 
squamous epithelium, attached to a basement membrane. The vaginal epithelium consists of 
approximately 28 cell layers on days 1-12 of the menstrual cycle, with a slight thinning to 26 on days 
19-24 of the cycle [12]. The thickness of this epithelium has been measured as 261 ± 16 μm [13]. This 
stratified squamous epithelium is a main permeability barrier of the vaginal [14]. This barrier function 
is supported by the production and presence of amorphous intercellular lipids and membrane coating 
granules extruding ceramides, glucosyl-ceramides and cholesterol [15]. The vagina has been found to 
be 62.7  11.25 mm in length, and 27.2  4.79 mm in width at the mid-lower vagina from an MRI study 
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of 28 women [16]. The surface area of the vagina has also been measured from casts, and ranged from 
65.73 to 107.07 cm2 with a mean of 87.46  7.80 cm2 [17]. The diffusion of tritiated water through 
human cervical and vaginal tissue gave measured apparent permeability coefficients of 8×10−5 cm/s 
and 7×10−5 cm/s, respectively [18]. The permeation of tritiated water through human vaginal 
epithelium is not statistically different than the permeation through human ex vivo buccal mucosa 
[19]. The vagina is approximately 16-times more permeable to water than skin, using published values 
for skin permeability [20].  
 
2.2.  THE COMPOSITION AND VOLUME OF VAGINAL FLUID  
The vagina is lubricated by vaginal fluid, which is a mixture of fluids from the upper reproductive tract, 
such as cervical mucus and endometrial fluids and transudate from the vaginal walls [21]. Bartholin’s 
glands, positioned either side of the posterior section of the vaginal opening also serve to aid 
lubrication of the vagina, secreting relatively small amounts of fluid during sexual arousal [22]. 
Positioned either side of the anterior of the vaginal opening are Skene’s glands, which perform a 
similar function. The constituents of vaginal fluid are water (90-95 %), mucins, carbohydrates, urea, 
salts, immunoglobulins, fatty acids, albumin, and other minor components [23]. Human cervicovaginal 
fluid also contains proteolytic enzymes, particularly serine and cysteine proteases [24]. 
Several studies have looked at the volume of vaginal fluid, providing useful estimates for 
pharmaceutical testing. Stone and Gambles’ study of 113 healthy women, found a mean quantity of 
0.76 g of fluid present [25]. The total vaginal fluid volume has been measured in 38 HIV-1 infected 
woman by Mitchell et al [26], and had a median value of 0.51 mL. The rate of fluid production was 
measured by Godley [27] as 1.55 g/8 h. This reached a peak of 1.96 g/8 h mid-cycle and was reduced 
to 1.38 and 137 g/8 h either side of ovulation. This cyclical variation was not seen in women taking the 
oral contraceptive pill [27]. These studies are consistent with the vagina having a low fluid volume, 
which is replenished during the course of the day. It is noteworthy that vaginal fluid volume increases 
substantially during sexual stimulation, which may be a consideration for some applications [21]. The 
composition and quantity of vaginal fluid is of great importance for intravaginal gel products, as these 
factors may affect the degree of swelling, retention and release rates. Although the United States 
Pharmacopeia (USP) has no standard recipe for simulated vaginal fluid, it references the simulated 
vaginal fluid of Marques et al [28] as a medium for drug release testing. Generally, simulated vaginal 
fluids typically have an acidic pH, of approximately pH 4, and may or may not include mucin. 
 
2.3. THE VAGINAL MICROBIOME AND PH OF THE VAGINA 
A healthy vagina has a diverse microbiome which maintains an acidic pH via the metabolism of 
glycogen to D/L lactic acid by bacteria, mainly of the genus Lactobacillus [29,30]. The bacteria of the 
vagina also have a protective role against pathogens, by reducing pH, producing bactericidal 
compounds and by competitive exclusion [30]. Women tend to have one of five microbial 
communities, dominated either by L. iners, L. crispatus, L. gasseri, L. jensenii, or a fifth community 
having lower proportions of lactic acid bacteria and higher proportions of strict anaerobes [30].  
The pH of the vagina is typically between 3.5 and 5.5 [29]. During pregnancy, the pH of the vagina 
changes to 3.8-4.4; after menopause, the pH increases to 7.0–7.4, due to variation in glycogen content 
at these times [28]. The pH of the vagina is increased to approximately pH 7 during coitus by the 
infusion of seminal fluid [31]. Ethnicity also appears to affect vaginal pH. The average measured 
vaginal pH values of Hispanic (pH 5.0 ± 0.59) and black (pH 4.7 ± 1.04) women were higher than found 
for Asian (pH 4.4 ± 0.59) and white (pH 4.2 ± 0.3) women [30]. This ethnic difference is important to 
consider from a drug delivery standpoint, as formulations that require specific pH triggers may be less 
efficacious in certain ethnic groups of women and the absorption of ionisable drugs may be affected. 
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2.4. CERVICAL MUCUS – PRODUCTION, PROPERTIES, AND COMPOSITION. 
As discussed previously, the vaginal fluid contains mucus from the cervix, the properties of which vary 
dependant on the menstrual cycle. The mucus produced in the cervix can be designated as type E or 
G, and is always a mixture of the two, the ratio of which depends on the time of the menstrual cycle. 
Type E mucus is controlled by estrogen dominance before and during ovulation, and is thin and 
watery. Type G mucus is controlled by progesterone dominance post-ovulation and is thick and sticky 
to stop the passage of sperm into the uterus. Type G mucus is dominant for women taking the 
combined oral contraceptive pill [11]. The primary components of cervical mucus are mucins. Mucins 
are glycoproteins coded for by the MUC gene family, from which they get their names and may be 
either transmembrane or gel-forming (secretory). Mucins have large molecular weights (up to tens of 
MDa) and are up to 80 % oligosaccharide by volume [32]. Carlstedt et al [33] analysed cervical mucus 
released from pregnant women prior to giving birth and found it to contain large amounts of proline, 
threonine and serine residues, consistent with mucins found elsewhere in the body. Additionally, 
cysteine residues were identified, which have been attributed as promoting gel formation via 
disulphide bridging [34]. Overall, the protein content of the mucin glycoproteins was 19.9  0.8 % 
(w/w) [33]. The O-glycans adorning mucin contains both neutral (N-acetylgalactosamine, N-
acetylglucosamine, galactose, and fucose) and acidic (sialic acid) sugar moieties [33]. Andersch-
Björkman et al [35] found that cervical mucins isolated from 6 individuals contained three gel-forming 
(MUC5B, MUC5AC, and MUC6) and two transmembrane mucins (MUC16 and MUC1). It has also been 
found that mucus production in the cervix increases to 600 mg/day mid-cycle from 20-60 mg/day at 
other points of the menstrual cycle [36]. 
 
2.5 IMPROVING RETENTION IN THE VAGINA THROUGH MUCOADHESION 
The retention of semi-solid dosage forms in the vagina is typically poor due to the presence of 
moisture, lubricative mucus and shear forces. There is often a need to attempt to enhance retention 
in the vagina using excipients which enhance adhesion to the vaginal mucosa. These so-called 
“mucoadhesive” excipients enhance retention by a number of different mechanisms, which have been 
extensively reviewed elsewhere and are briefly summarised here with emphasis placed on those 
relevant to semi-solid dosage forms [34,37–40]. 
The mucoadhesion process can be thought of as the result of a plethora of underlying mechanisms. 
Highly viscous materials are better able to resist the shear found in the vagina and the natural 
tendency to flow out of the vagina. The rheology of the dosage form also affects the spreading of the 
gel throughout the vagina; with thixotropic or pseudoplastic gels easily spread. Spreading is aided by 
the ability of the gels to wet across the mucosa. After this initial ‘contact’ stage, the gel can 
‘consolidate’ its adhesion to the mucosa with further physical and chemical interactions. Hydrogen-
bonding between excipients and mucosa is believed to play a great role, due to the oligosaccharide 
side-chains of the mucin, though other interactions such as electrostatic and ion-dipole interactions, 
may also play a part [34]. Hydrophobic interactions may also occur due to the loss of entropy of water 
molecules as they solvate hydrophobic regions of a macromolecule in solution. There are also 
mucoadhesive materials designed to form covalent bonds with mucins, such as “thiomers” which 
bond to thiol groups present in the mucin glycoproteins [41–43]. Consolidation of mucoadhesive 
interactions may also occur through polymer chain interpenetration into the secretory mucus gel 
found on the surface of mucosal membranes [44]. 
 
3.  INTRAVAGINAL DOSAGE FORMS AND THEIR APPLICATIONS  
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3.1 INTRAVAGINAL DOSAGE FORMS  
There are several common dosage forms used in intravaginal drug delivery. Gels and creams are 
common semisolid dosage forms for the delivery of drug over short periods, with repeated 
application. Suppositories/pessaries are also available, often marketed as “ovules”, and are typically 
composed of glycerol-gelatin bases; as PEGs and fatty bases are likely to cause irritation. For drug 
delivery over longer periods, intrauterine devices or vaginal rings may be used. These may use 
“reservoir” delivery techniques for prolonged delivery over months/years. Vaginal rings may be 
composed of silicon or polymer elastomers, whereas intrauterine devices are often made of polymers 
with increased rigidity, such as ethylene-vinyl acetate copolymers. There are a number of less common 
dosage forms, such as films, sponges, and vaginal tablets. 
 
3.2.VAGINAL INFECTIONS – BACTERIAL VAGINOSIS, CANDIDIASIS, AND TRICHOMONIASIS 
Infections of the vagina typically result in inflammation, causing itching, discharge and pain while 
urinating or during coitus [45]. This ‘vaginitis’ also encompasses irritation arising from epithelial 
abnormalities and other conditions [46]. Vaginal infections/disorders are most commonly either 
bacterial vaginosis, candidiasis, and trichomoniasis. Medicines for vaginosis treatment are outlined in 
table 1. Bacterial vaginosis is the result of a shift in the composition of the vaginal microbiota from 
protective lactobacilli to pathogenic anaerobic bacteria. Antibiotics are administered for treating 
bacterial vaginosis, and can be taken either orally or intravaginally. It has been reported that 
intravaginally administered antibiotics are as efficacious as those orally administered and have the 
advantage of lower systemic effects [47]. Candidiasis is a vaginal infection arising from yeasts of the 
genus Candida. Candidiasis results in itching, burning and white discharge from the vagina [48]. 
Candidiasis can be treated locally and orally by the administration of antifungals [48]. Trichomoniasis 
is a disorder caused by the protozoan Trichomonas vaginalis. It often appears to be asymptomatic, 
but is associated with increased risk of human immunodeficiency virus infection and may cause 
women issues during pregnancy [49]. Trichomoniasis is typically treated with oral antiprotozoals, such 
as metronidazole or tinidazole [49]. There are, however, some intravaginally administered treatments 
[50]. 
Table 1: Intravaginally-administered medicines and their applications 
Application Medicine Composition  
Bacterial Vaginosis Zidoval®  0.75 % metronidazole gel [51]  
 Dalacin®  2 % clindamycin cream [51]  
 Flagystatin® Suppository containing 500 mg metronidazole plus 
10000 units nystatin [52] 
Candidiasis Clotrimazole  Pessary with 500 mg clotrimazole [51] 
 Canesten® 1 % clotrimazole cream [51] 
 Gyno-Daktarin® Suppository containing 1.2 g miconazole nitrate [51] 
Trichomoniasis Neo-Penotran® Suppository containing 750 mg of metronidazole plus 
200 mg of miconazole [50] 
Hormonal 
Contraception 
NuvaRing® [53] Oestrogen and progestogen-containing intravaginal 
ring made of ethylene vinyl acetate. 
 Progering® [53] Progestogen-containing intravaginal ring made of 
silicone elastomer. 
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Spermicides Vaginal Contraceptive 
Film® [54] 
Nonoxynol-9 - containing, dissolves in vaginal fluid to 
create a gel. Film contains poly(vinyl alcohol) [55]. 
 Today® sponge [54] Concomitantly blocks cervix and releases nonoxynol-
9. Sponge made of polyurethane [55]. 
Cervical Ripening Cervidil®/ Propess® 
 
Vaginal insert containing cross-linked polyethylene 
glycol. Controls release of dinoprostone over 24 h 
 Prepidil® / Prostin E2 
vaginal gel 
Dinoprostone gel formulation, containing colloidal 
silicon dioxide [55]. 
Glandin-E2 Vaginal tablet containing dinoprostone 
 Misodel®/Mysodelle® Vaginal insert containing misoprostol  
Supplementation of 
endogenous bacteria 
Purfem Suppository containing two strains of lactobacilli 
FloraFemme Suppository containing various strains of lactobacilli 
and bifidobacteria 
3.3. CONTRACEPTION USING HORMONES AND SPERMICIDES  
Drugs can be administered intravaginally for contraceptive purposes (table 1). These drugs will be 
either hormones, to reduce fertility, or spermicides. Hormonal contraceptives delivered by the vaginal 
route are either combination oestrogen/progestogen or progestogen-only [56]. Progestogen and 
oestrogen are steroid hormones which can prevent ovulation and increase the thickening of cervical 
mucus, reducing the likelihood of conception. Spermicides aim to immobilize sperm so that they 
cannot fertilise. The most commonly marketed spermicide is nonoxynol-9, a surfactant which 
damages the membrane of spermatozoa.  
3.4.CERVICAL RIPENING THROUGH PROSTAGLANDIN USE 
In recent years there has been a greater number of labour inductions, largely due to patient choice 
[57]. Labour induction can achieved by chemical methods (table 1), often by the intravaginal 
administration of prostaglandins. Two intravaginally administered prostaglandins are dinoprostone, a 
trade name for prostaglandin E2, and misoprostol, a synthetic prostaglandin E1 analogue [58]. These 
prostaglandins have been formulated into vaginal gels and inserts, as summarised in table 1. It has 
been demonstrated that Prepidil, a vaginal gel, gave a shorter induction-to-vaginal delivery interval 
with less expense than the Cervidil implant, and had no greater occurrence of adverse events [59].  
3.5. PRE-EXPOSURE HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROPHYLAXIS 
HIV is a sexually transmitted virus, with HIV-1 and HIV-2 subtypes.  Male-to-female transmission of 
HIV occurs via seminal fluid, which contains infected cells as well as free virus. The HIV infection can 
be transmitted through the squamous epithelia found lining the vagina and ectocervix, as well as the 
columnar epithelia of the endocervix, followed by the infection of CD4 cells [60]. Whilst the use of 
condoms is effective in the prevention of HIV, there are groups of women who are often unable to 
negotiate their use, in particular, sex workers [61]. In order to provide HIV protection for those who 
are unable to negotiate condom use, there have been efforts to develop intravaginally administered 
HIV protection. 
There have been several clinical trials looking at the efficacy of vaginally administered antiretrovirals 
in the prevention of HIV transmission. The progress of these trials for gel products is discussed later 
in the review. PrEP has also been attempted using intravaginal rings, which allow for the controlled 
release for over a month [2]. This reduces the necessity of patients’ adherence to dosing regimens, 
and thus aims to improve prophylaxis. The efficacy in reducing HIV transmission of a silicone vaginal 
ring containing dapivirine, a non-nucleoside HIV-1 reverse-transcriptase inhibitor, was the subject of 
two phase III clinical trials, “the ring study” and “ASPIRE”. ASPIRE found that HIV-1 infection was lower 
by 27 % in women using dapivirine intravaginal rings, relative to control [62]. Furthermore, a 37 % 
reduction in HIV transmission was found when excluding data from sites with low adherence and 
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retention. A 56 % reduction was found among women older than 21 years of age, who had greater 
levels of adherence. “The ring study”, conducted in 1959 women (1762 in South Africa and 197 in 
Uganda) over two years, found that there was a reduction in HIV transmission of 30.7 % in women 
using the dapivirine ring [63]. This figure was increased to 37.5 % in women over 21. The 
aforementioned clinical trials demonstrate the potential for pre-exposure HIV prophylaxis via 
intravaginal administration of antiHIV agents and is certain to increase interest in this field. 
3.6.THE SUPPLEMENTATION OF ENDOGENOUS BACTERIA FOR PROPHYLAXIS AND THE TREATMENT 
OF BACTERIAL VAGINOSIS 
It has been suggested that ‘probiotic’ bacteria administered vaginally may be able to promote 
vaginal health, and even treat bacterial vaginosis. This is due to the belief that the dominance of 
probiotic microorganisms in the healthy vagina maintains an environment in which pathogens are 
unable to grow to infectious levels. There are numerous medicines containing bacteria of the genii 
Lactobacillus and Bifidobacterium for vaginal administration. Published clinical trials claim efficacy of 
probiotic treatment for bacterial vaginosis [64,65], however literature reviews [66,67] and a 
Cochrane review [68] have cast doubt on the findings of these clinical trials, indicating that larger, 
better designed, clinical trials are required before any strong conclusions may be drawn. 
Additionally, it has been shown that women respond positively to probiotic treatment regardless of 
clinical response, meaning that any non-blinded studies may be highly misleading [69]. 
 
3.7 APPLICATORS FOR VAGINAL GELS 
Gels are typically administered using an applicator to ensure effective insertion into the body of the 
vagina and to reduce messiness. For most products an applicator with a design analogous to a wide-
bore syringe is used; an example is shown in reference [70]. The opening of the syringe may screw 
onto a tube containing the gel preparation to reduce messiness during filling of the applicator. Some 
semi-solid products are prepared in single-use pre-filled applicators. For instance, Canesten® 
intravaginal cream is prepared as a pre-filled barrel, into which a plunger is placed by the patient to 
initiate application of cream after insertion into the vagina. The traditional applicators described 
thus far administer gel most effectively to the upper vagina and cervix, and less of the dose is spread 
to the lower parts of vagina. Distributing the gel more homogeneously may aid systemic permeation 
or assure local action across the vagina. Omar et al [71] designed an applicator with multiple 
openings which aids spreading of gel in the vagina. This applicator was investigated for use in a 
spermicide product, the “Invisible Condom®” [72]. 
 
4.0  POLYMERIC GELS IN INTRAVAGINAL DRUG DELIVERY 
Aqueous solutions of macromolecules may form macroscopic gels due to physical entanglement or 
chemical bonding between polymer chains. Polymer gels used for intravaginal drug delivery are 
typically viscous, aiding retention in the vagina and display pseudoplastic or thixotropic behaviour to 
aid spreading of the dosage form during application. A number of pharmaceutical grade excipients 
have been studied for intravaginal application, including polysaccharides and synthetic materials. 
Some common examples are shown in Figure 2. Within this review, polymeric gel products have been 
separated intro traditional gels, synthetic gels, gels containing particulates, and thermogelling 
materials. 
8 
 
 
 
Figure 2. The chemical structure of some polymers commonly used in intravaginal drug delivery 
 
4.1 TRADITIONAL GELS COMPRISED OF HYDROPHILIC POLYMER SOLUTIONS 
 
This section discusses “traditional gel” products, i.e. those composed of natural or commercially-
available polymers without stimuli-responsive behaviour. These medicines have the advantage of 
being simple to produce and many have a history of use in pharmaceuticals. Additionally, simple 
formulation approaches, such as multicomponent blending, allows for these traditional gel products 
to have altered properties without introducing any novel components with an associated regulatory 
risk.  
Ahmad et al [73] studied the effect of various water-soluble polymer gels on the release of 
clotrimazole and metronidazole. The polymers hydroxypropyl methylcellulose (HPMC), sodium 
carboxymethyl cellulose (Na-CMC), xanthan gum, guar gum, sodium alginate, carbopol and 
polycarbophil were chosen as they are known bioadhesives. Carbopol and polycarbophil are both 
cross-linked poly(acrylic acid) derivatives, with the cross-linking agent and degree of cross-linking 
dependent on the grade. It was found that altering gel composition could change total release times 
from 1 to 5.5 h. Bioadhesion was determined on bovine vaginal mucosa using a texture analyser, which 
demonstrated that the force of bioadhesion was dependent on gel composition. Unfortunately, gel 
preparations were too complex to identify any obvious attributes leading to improved bioadhesion.   
Polycarbophil and carbopol were used to deliver a poorly water-soluble salicylidene acylhydrazide 
compound by Pedersen et al [74]. A solubility enhancer, cremaphor, was used to allow the compound 
to be dissolved in the aqueous gel. The gel preparation retarded drug release by twenty-fold relative 
to a control of drug alone in a DMSO/buffer mixture. Furthermore, these formulations were 
efficacious in halting the transmission of Chlamydia trachomatis in a mouse model, which 
demonstrated a 68 % reduction in infection relative to control. Carbopol alone has been used by Gupta 
et al [75] to deliver sperm immobilising factor to produce a gel product which was able to immobilised 
spermatozoa within 20 s. 
Kiser et al [76] have used a “design of experiments” method to optimise combination gels of Carbopol 
974P and hydroxyethylcellulose (HEC) with respect to their rheology, in vitro drug release, and 
performance in permeability studies. Within the article they define two types of vaginal gel 
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rheologically; a “spreading” gel and a “bolus” gel. The spreading gel aims to provide ease of application 
by effective spreading into the vagina. However the bolus gel takes a different approach; by being 
more resistant to flow, the gel should exhibit greater retention in the vagina. Gel composition was 
related to the in vitro release rate of tenofovir and UC781 (a non-nucleoside reverse transcriptase 
inhibitor). Whilst the authors state that tenofovir release rate was largely independent of 
composition, the release of UC781 reached a maximum at low HEC levels and higher carbopol 
concentrations. Cumulative release plots revealed that tenofovir, which was soluble in the gels, was 
released rapidly in vitro, but the release of UC781, administered as a dispersion, occurred slowly over 
8 h. The greater impact of gel composition on release of UC781 was related to the differences in 
viscosity of the gels affecting the dissolution of dispersed drug.  
“Box-Behnken” statistical design was used by Chopra et al [77] to optimise gel formulations of 
Carbopol 934P, Carbopol 974P and Polycarbophil, in combination with honey as a bioactive and aerosil 
(fumed silica) as a thickener. Formulations were optimised for greatest gel strength and 
mucoadhesion. The release of honey from the gels occurred in a “burst” manner over 4 h, with release 
continuing over a 24 h period. The burst release phase was zero order, whilst the second phase was 
non-Fickian, as determined by the Korsmeyer–Peppas model. This non-Fickian diffusion was 
attributed to a combination of polymer hydration, drug dissolution and erosion. 
 
Chitosan gels containing lactic acid for the maintenance of acidic vaginal pH have been studied [78]. 
It was also found that, despite its lower viscosity, a “medium” molecular weight chitosan had a greater 
mucoadhesion than “high”, as measured using a texture analyser on ex vivo vaginal mucosa. This was 
put down to the greater mobility of the lower molecular weight chitosan allowing for improved 
interpenetration between gel and mucosa. The release of lactic acid from these gels occurred over 7 
h. Increasing chitosan molecular weight retarded release, whilst increased lactic acid loading 
accelerated release rates from the dosage form. In a separate study, the retention of chitosan in the 
vagina of live rats was studied using infrared imaging techniques [79]. It was found that 2 % chitosan 
gels of three molecular weights, 20, 200, and 800 kDa, were well retained over a 24 h time period. 
Texture analysis indicated that the work of adhesion of the 20, 200 and 800 kDa chitosan gels was 
222.329 ± 5.199, 253.510 ± 38.041 and 426.538 ± 63.285 N mm s-1, respectively, indicating an effect 
of molecular weight not seen in vivo. Chitosan, hydroxypropyl methylcellulose, and poloxamer 407 
were used by Tugcu-Demiröz et al [80] as gel-formers to deliver oxybutynin, an antimuscarinic,  via 
the vaginal route. Texture analysis demonstrated that HPMC was the most mucoadhesive. Using a 
diffusion chamber to measure permeation through vaginal tissue gave the rank order chitosan > 
HPMC> poloxamer 407. An In vivo study on rabbits demonstrated that administration of oxybutynin 
in chitosan or HPMC gels via the vaginal route gave a 79 % or 19 % improvement in bioavailability 
relative to the oral route, respectively. 
 
4.2 “BESPOKE” SYNTHETIC POLYMERS FOR INTRAVAGINAL DRUG DELIVERY   
Several novel synthetic materials have been reported for use in intravaginal drug delivery. Whilst novel 
materials have a greater regulatory risk, they often have improved functionality relative to traditional 
gel products. Within gel products, synthetic approaches usually aim to improve mucoadhesion to the 
vagina, either by increasing the strength of interaction between dosage form and mucosa, or allowing 
for gelation in situ. 
VivagelTM is a product for the treatment of bacterial vaginosis, and for STI prevention. VivagelTM 
contains a generation 4 lysine dendrimer with naphthalene disulfonic acid surface groups contained 
in a Carbopol gel to enhance retention. VivagelTM is able to bind to HIV surface proteins (gp120), 
inhibiting the binding of the virus to its cellular targets [81].  
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In situ gelling systems have been reported by Navath et al [82]. Dendrimers bearing thiol groups were 
able to form hydrogels within 10 seconds after mixing with 8-armed PEG thiol, due to disulphide bridge 
formation. This led to an injectable in situ gelator which was able to release amoxicillin over 10 days. 
The rate of release could be retarded by increasing the concentration of gel and no dose-dumping was 
found. An In vivo study using a pregnant guinea pig model over three days showed that gels were well 
tolerated by the animals and showed that there was no sign of changes in vaginal pH or skin-
reddening. The gels showed some loss of retention after 2 days, moving away from the cervix into the 
vaginal cavity (figure 3). 
 
Figure 3. Dendrimer-based in-situ gelling hydrogel (orange) in the reproductive tract of guinea pigs 
after 5 h (A), 12 h (B), 2 days (C), and 3 days (D). C: cervix, V: vagina, U:Uterus [82]. Reprinted with 
permission [82]. Copyright 2011. American Chemical Society. 
Mucoadhesive vaginal gels containing a mixture of chitosan, or its derivative 5-methyl-pyrrolidinone-
chitosan and HEC were designed by Perioli et al [83] for the delivery of metronidazole. The gels 
produced with 5-methyl-pyrrolidinone-chitosan had improved mucoadhesion and released 
metronidazole over 90 minutes. The chitosan derivative also had lower viscosity than the constituent 
chitosan, which the authors suggest would allow for ease of extrusion from a syringe or applicator. 
Friedl et al [84] report the use of a “preactived thiomer” for use in intravaginal drug 
delivery.“Preactivated” thiomers are polymers bearing protected thiol groups, which are able to bind 
to cysteine residues of mucin. In the study, chitosan was coupled with thioglycolic acid using 
carbodiimide chemistry, followed by protection of thiol moieties with 2-mercaptonicotinic acid to give 
the preactivated thiomer. Mucoadhesion of polymer solutions was determined using a flow-through 
method, which demonstrated that the preactivated chitosan thiomer had improved retention on 
vaginal mucosa relative to commercial formulations. This improvement in mucoadhesion was also 
demonstrated using texture analysis and the rheological method of Hassan and Gallo [85]. Thiolated 
carbophil and chitosan have been explored by Cevher et al [86] for the intravaginal delivery of 
clomiphene citrate. Thiolation improved mucoadhesion, but it was also found to improve the 
cohesiveness and elasticity by texture profile analysis. The latter effect is potentially the result of 
internal disulphide bond formation enhancing cross-linking density. It was also found that carbophil 
and its thiolated derivative were able to sustain the release of clomiphene citrate over 72 h, whereas 
the chitosan gels delivered the drug over 12 h. 
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4.3 GELS CONTAINING PARTICULATES FOR MODULATED DRUG DELIVERY 
The incorporation of particulates into vaginal gel formulations is often reported as a means of 
sustaining the release of bioactives. For water-soluble bioactives, gel preparations typically release 
their load over several hours, whereas microparticulates are capable of releasing drug over months. 
However, particulates are capable of causing mechanical irritation to the vagina, and it is generally 
recommended that particulates should be under 50 µm diameter to avoid discomfort [87]. 
Pavelic´ et al [88] incorporated liposomes into carbopol gels to form novel drug delivery systems which 
intended to combine the proposed controlled release properties of liposomes with the improved 
retention of gels. The “liposomal gels” slowed release of a hydrophilic fluorophore over 24 h relative 
to a control of carbopol, releasing approximately 16 % and 36-42 % of fluorophore, respectively. In a 
later publication, the authors used liposomes of egg phosphatidylcholine and egg phosphatidyl- 
glycerol–sodium in carbopol to deliver clotrimazole and metronidazole, releasing approximately 75 % 
and 60 % of their entrapped drug over 24 h. Acyclovir-containing liposomal gels were also studied, 
which again demonstrated controlled release of 65 % of encapsulated acyclovir over 24 h [89]. Chen 
et al [90] fabricated a dual pH- and temperature- responsive vaginal drug delivery system containing 
liposomes incorporated into a pluronic thermogelling material. Liposomes of methoxy polyethylene 
glycol 2000-hydrazonecholesteryl hemisuccinate were synthesised to create a pH-triggered delivery 
system. Arctigenin, a plant lignan, was encapsulated into these liposomes, which were subsequently 
dispersed in an aqueous pluronic mixture. These systems gave little to no release of arctigenin at pH 
7.4 and pH 9.0, delivering ca. 5 % of their payload over 72 h. Once pH was reduced to 5.0, 
representative of vaginal fluid, arctigenin was released in a controlled manner over ca. 24 h. In 
addition to liposomes, solid particulates have been investigated as controlled release devices in 
vaginal gels. Chatterjee et al [91] have shown incorporating Zidovudine (an NRTI) into a bioadhesive 
carbopol/HPMC gel allowed for controlled release over 24 h. This was mirrored in plasma 
concentration measurements in rabbits. The authors also investigated the use of 50 um ethylcellulose 
microcapsules within these gels to control zidovudine release [92].  However, the particles used 
showed some irritancy in vivo. Solid Eudragit RS 100 and Eudragit S 100 nanoparticles measuring 200 
nm were incorporated into a chitosan gel by Frank et al [93]. It was found that incorporating 
nanoparticles into a 2.5 % chitosan gel improved adhesion to porcine vaginal mucosa, as determined 
using a texture analyser. This improved mucoadhesion was not seen, however, using a flow-through 
method. It was also found that these nanoparticulates were able to aid the penetration of a 
fluorophore into vaginal tissue. 
 
4.4 Thermogelling materials for intravaginal drug delivery 
Thermogelling materials are polymeric solutions which undergo a sol-gel transition upon warming 
above a specific gelation temperature. Thermogelling materials with a gelation temperature between 
25-37 °C are of particular interest in intravaginal drug delivery as they are able to flow through an 
applicator before forming a viscous gel in the vagina. This reduces the messiness of the application 
process, and enhances retention in the vaginal cavity due to the gel’s greater resistance to shear and 
dilution. Thermogelling systems are usually block-copolymers which transition from hydrophilic to 
amphiphilic above a given temperature. Mechanistically, this may be caused by the self-assembly of 
micelles at raised temperature leading to “micelle-packing” (figure 4) or the dehydration of one block 
above its lower critical solution temperature, leading to physical cross-linking. The majority of 
thermogelling systems for intravaginal administration use poloxamer 407 (also known as pluronic 
F127) as the temperature-responsive component, as it is inexpensive and already in use in 
pharmaceuticals. The pluronics are poly(ethylene oxide) – poly(propylene oxide) – poly(ethylene 
oxide) triblock copolymers, with differing block lengths. 
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Figure 4. A proposed mechanism for poloxamer 407 gelation at raised temperatures. Poloxamer 
consists of PEG blocks (red) and polypropylene blocks (blue).  
Poloxamer 407 and 188 have been used to form thermogelling systems to delivery econazole nitrate 
intravaginally [94].  Altering the ratio of pluronics allowed for modification of gelation temperature 
and rheological behaviour. It was found that particular blends of poloxamer 407 (15-20 %) and 
poloxamer 188 (10-20 %) gave steady econazole release over 8 h. The release profiles demonstrated 
non-Fickian diffusion, typical for poloxamers. Ibrahim et al [95] also used thermosensitive poloxamer 
407 and 188 mixtures for metronidazole delivery. It was found that increasing the concentration of 
poloxamer 407 from 15 to 30 % led to a reduction in gelation temperature from >40 °C to 10 ± 1 °C. It 
was also found that mucoadhesive force increased with concentration and by the addition of 
poloxamer 188, which was attributed to specific interactions between F68 and the mucosa. This effect 
was also seen by Aka-Any-Grah et al [96]. A formulation of 20 % poloxamer 407 and 10 % poloxamer 
188 was taken on for further evaluation, which had a gelation temperature of 28 °C. It was found that 
this formulation released 90 % of its metronidazole load over 12 hours in a more sustained manner 
than a commercial formulation, Tricho® gel. In a 4 week clinical trial, the pluronic gel showed a 
significant improvement in cure rate relative to the conventional vaginal gel group (80 versus 47 %, 
respectively, p = 0.034). It should be noted, however, that few details of the study are included within 
the publication, and that the sample size was small (n = 20). Aka-Any-Grah et al [96] also studied 
mixtures of poloxamer 407 and 188, and found that the incorporation of poloxamer 188 improved the 
gel’s resistance to dilution in simulated vaginal fluid. The authors do demonstrate, however, that this 
improvement in elasticity is a result of the increase in overall pluronic content, and not a result of 
specific synergy polymers. 
Chang et al [97] devised a thermogelling systems comprised of poloxamer 407, poloxamer 188, and 
polycarbophil for intravaginal administration of clotrimazole. Increasing polycarbophil or poloxamer 
188 content improved mucoadhesion, but also increased the work needed to expel the formulations 
through a syringe. Controlled release was demonstrated over 8 h for formulations with poloxamer 
407, poloxamer 188, and polycarbophil ratios of 15/15/0.2 and 15/20/0.2. Release rates were lower 
in the 15/20/0.2 formulation, which the authors suggest could be correlated with the increased 
viscoelastic modulus of that preparation hindering drug diffusion. 
Thermogelling poloxamer 407 systems containing propolis and carbopol 934P have been studied by 
Pereira et al [98]. Propolis is a resin collected by bees, which has fungicidal activity. 15 % (w/w) 
poloxamer 407 and 0.25 % carbopol 349P (F15/0.25) or 20 % (w/w) poloxamer 407 and 0.15 % 
carbopol 349P (F20/0.15) released approximately 70 and 90 % of propolis over 24 h, in a controlled 
manner with no burst release, respectively.  
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Andrews et al [99] investigated complex gel formulations containing HEC, polyvinylpyrrolidone (PVP), 
Poloxamer 407 (PL), and either polycarbophil (PC) or poly(methylvinylether-co-maleic anhydride) as 
mucoadhesive agents. These so-called “rheologically-structured fluids” displayed several properties 
commensurate with an effective vaginal drug delivery vehicle. Some formulations underwent sol-gel 
transition at 15 °C, which would allow the preparation to flow through an applicator before gelation 
in situ. Furthermore, the gels were resistant to dilution in simulated vaginal fluid. The release of 
erioglaucine dye was controlled over the 24 h measurement window (figure 5).  
 
Figure 5. Erioglaucine release from gel blends containing poloxamer 407. (Filled square) HEC 5%/PC 
3%/PL 10%/PVP 4% (w/w); (Filled triangle) HEC 5%/PC 3%/PVP 4%; (w/w); (open triangle) HEC 
5%/Gantrez 3%/PL 10/PVP 4% (w/w); (open square) HEC 5%/GANT 3%/PVP 4% (w/w). Reused from 
Andrews et al [99] with permission from ACS. Direct link: 
http://pubs.acs.org/doi/abs/10.1021/bm9003332.  
“Rheologically structured fluids” have also been investigated for the intravaginal delivery of 
recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 for vaginal immunisation 
[100]. HEC at 3 and 5 % was mixed with polycarbophil, and poly(vinylpyrrolidone). Increasing HEC 
concentration from 3 to 5 % resulted in increased viscosity from 134 ± 9 Pa.s to 200 ± 5 Pa.s (at 1.14 
Hz), but a reduction in mucoadhesion. Directly placing the gels into a phosphate buffered saline + 
Tween solution allowed for the in vitro release of the protein to be measured by ELISA. Over 24 h, 45.7 
% of CN54gp140 was released from the 3% HEC “rheologically structured” gel, whilst 57.36 % was 
released from a HEC control gel. Another control, carbopol alone, released 98.17 % of its load over 20 
minutes. This demonstrated that the complex “rheologically structured fluids” sustained the release 
of protein better than their constituent components, consistent with the greater overall polymer 
concentration. Once administered intravaginally, the optimised dosage forms were able to elicit 
immune response in rabbits. 
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Kim et al [101] used a thermogelling system comprised of pluronic derivatives designed to break down 
in the acidic environment of the vagina. Amphotericin B was incorporated into the gels within a 
hydroxypropyl--cyclodextrin inclusion complex. This led to gels which gave a pH-triggered release at 
the slightly acidic pH of the vagina (pH 5), delivering ~ 50 % of the incorporated amphotericin B over 
4 h. The materials produced were found to be nontoxic to HEK293 cells and did not show inflammation 
or necrosis to murine vaginal tissue as determined by histology. The incorporation of clotrimazole-
cyclodextrin inclusion complexes into gels containing poloxamer 407 has been studied by Bilensoy et 
al [102]. These gels allowed for controlled release of clotrimazole over 100 h, with no burst release. 
The effect of k-carrageenan on the release rate of acyclovir from poloxamer 407 gels was studied by 
Liu et al [103]. It was reported that poloxamer 407 gels suffered from rapid erosion in vaginal fluid, 
leading to immediate drug release. It was found that the addition of carrageenan significantly 
decreased the release rates, slowed dissolution and hindered gel erosion in a concentration-
dependent manner. Carbopol was then added to the formulations to improve mucoadhesion. In a rat 
study, it was found that the poloxamer, carrageenan, and carbopol complex gels retained acyclovir in 
the vagina up to a 12 h measurement point, whilst controls of poloxamer alone, poloxamer + carbopol, 
and poloxamer + carrageenan did not (Figure 6). 
 
Figure 6. Blending of carbopol and carrageenan into poloxamer 407 formulations improves the 
retention of acyclovir in the vagina of rats [103]. Reused with permission from Elsevier. 
Almomen et al [104] developed thermogelling glycol-chitosan hydrogels for intravaginal delivery of 
progesterone. Glycol-chitosan showed a concentration and pH dependent gelation temperature of 
between 15 and 30 °C. Incorporation of progesterone increased the gelation temperature of 5 % 
glycol-chitosan from 30.9±1.6 to 34.3±1.6 °C. Release of progesterone occurred over 4 h, in a biphasic 
manner, during which time the glycol-chitosan hydrogel eroded by approximately 50 %.  
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5.0 THE SENSORIAL PROPERTIES OF VAGINAL GELS 
The process of administering a vaginal gel is less familiar for the patient than, for example, taking a 
tablet or suspension orally. Furthermore, after administration, gel formulations may be perceptible to 
the patient, or interfere with other activities, e.g. coitus, leading to an unwillingness to apply a 
product. Thus, the sensorial experience of using intravaginal products is of great importance in 
assuring patient adherence and compliance to the treatment. This has been particularly damaging in 
HIV pre-exposure prophylaxis trials using gel products. Mehendale et al [105] studied the sensorial 
attributes of an intravaginal tenofovir gel and found that whilst women liked the ease of application, 
messiness and leakage of the product were disliked. In addition,  the microbicides were more accepted 
in women who used them in a coitally-dependent manner. Complaints of product leakage leading to 
poor patient adherence indicates that the effective retention of vaginal gels is important not just from 
the perspective of biological efficacy, but also that poor retention may reduce efficacy via a reduction 
in patient adherence. Mahan and co-workers [106] have attempted to link the rheology of commercial 
intravaginal products to their sensorial attributes, as measured using hand-feel by a sensory panel. 
Correlation could be made between rheological attributes and sensory perceptions of the product. 
Morrow et al [107] evaluated couples sensory perceptions of HEC gels verses vaginal film during 
coitus. Both female and male partners were found to have greater sensorial experiences with gels 
than films. It has also been found that the volume of gel used affects user sensory perception, with 
larger volumes of an HEC perceived as more lubricative and messy than lower volumes [108]. Van den 
Berg et al [109] explored the patient acceptability of long-acting topical vaginal gels. All of the products 
studied were shear-thinning commercial gels.  It was found that the women preferred gels with low 
viscosity for lubricative purposes, but for HIV/STI prevention a thicker gel would be preferred. Overall, 
the major concern of the study group was leakage of gel. It was also found that women responded 
positively to the idea of a gel that was initially thin, then thickened within a short time-frame. This 
supports the concept of in situ gelling products which increase in viscosity after application. These 
products include thermogelling polymer solutions which increase in viscosity upon warming, as well 
as thixotropic and pseudoplastic gels which reduce in viscosity during the application of shear. 
 
6.0 BARRIERS TO THE APPROVAL OF NEW INTRAVAGINAL MEDICINES – QUALITY, SAFETY AND 
EFFICACY 
The majority of published works focus on the understanding and optimisation of intravaginal gels, 
with little discussion of translation into a product. Herein is discussed some barriers to the approval 
of intravaginal medicines which must be carefully considered during product development. These are 
split into three key areas: quality, safety and efficacy (clinical trial). The regulatory information 
provided is taken largely from the United States Food and Drug Administration (FDA) and the USP. The 
FDA provides “guidance for industry” relevant to intravaginal drug delivery for specific applications, 
namely: vaginal microbicides for prevention of HIV infection [110]; vulvovaginal candidiasis (draft) 
[111]; bacterial vaginosis (draft) [112]; noncontraceptive estrogen drug products (draft) [113], 
estrogen and estrogen/progestin drug products (draft) [114] and vaginal contraceptive drugs [115]. 
There are no drug monographs relating to intravaginal gels available in the USP. The European 
Medicines Agency (EMA) provide some guidance for topical products, outlined in the relevant sections 
below. 
 
6.1 ASSESSING THE QUALITY OF INTRAVAGINAL MEDICINES 
The quality of a topical product must be thoroughly understood and characterised to satisfy regulatory 
bodies. The USP lists several product quality tests for topical products, some of these are “universal 
tests” which apply to all topicals, “specific Tests” to be considered as appropriate, and “specific tests 
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for topically applied semi-solid products”. These USP tests may be used as a benchmark to assure 
quality of a product. Universal tests cover qualitative description of product, identification tests to 
establish drug compounds present, assay to determine stability, and assessment of impurities. 
Quality-related tests applicable to vaginal gels are outlined in table 2. 
Table 2. USP tests for intravaginal gels 
Test Product Comments 
Minimum Fill All creams, gels, lotions, 
ointments, pastes, powders, 
aerosols, and sprays that are 
packaged in containers 
To ensure that the amount of material 
in the product conforms to that on the 
label. 
Uniformity of dosage units All topical and transdermal 
products 
Required for topicals intended for 
systemic delivery, or where deviations 
in concentration may cause irritation 
or undesired systemic exposure, and 
which are packaged in single-unit 
containers.  
Water content All topical and transdermal 
products 
 
Microbial Limits All topical and transdermal 
products 
For nonsterile products microbial 
acceptance limits apply 
Preservative content All topical and transdermal 
products 
Acceptance criteria must be 
established 
Antioxidant content All topical and transdermal 
products 
 
Sterility  All topical and transdermal 
products 
Must be ensured for certain 
applications e.g. woundcare 
pH All topical and transdermal 
products 
 
Particle Size All topical and transdermal 
products 
For disperse systems. May include 
evidence of any instability 
Crystal formation All topical and transdermal 
products 
Microscopic evaluation of crystal 
formation in product 
Apparent viscosity Topical Semi-solids May be established based on capillary, 
rotational, or rolling ball methods. 
Product-specific acceptance criteria 
need to be defined. 
Uniformity in containers Topical Semi-solids To ensure homogeneity of API content 
throughout container. 
 
In 2015, the EMA released a concept paper to develop guidelines on quality and equivalence in topicals 
(EM/CHMP/QWP/5581852014) [116]. This paper outlines current issues with the quality of topical 
medicines, in particular suggesting that shelf-life should be based not only on stability, but also on in 
vitro performance to ensure equivalence of product during storage.  The guidance also suggests the 
possibility of therapeutic equivalence waivers based on pharmaceutical equivalence of product. These 
guidelines are yet to be published and thus are not yet in place. 
Transmucosal products, i.e. those delivering drugs across the mucosa, are likely to incorporate 
quantities of drug higher than is intended to be delivered to the patient to ensure flux through the 
mucosa. The FDA recommends quantification of residual drug remaining in the product after it has 
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delivered its dose [117], as this may affect its safety, efficacy, and quality. It is recommended that the 
transmucosal product contain as little excess drug as possible so that residual drug be minimised. This 
can be achieved through formulation design, the use of penetration enhancers, and incorporation of 
mucoadhesives, so that drug may pass through the mucosa as efficiently as possible. 
 
6.2 ENSURING THE SAFETY OF POLYMERS FOR INTRAVAGINAL DRUG DELIVERY 
 
The safety of medicinal products must be assured through a series of in vitro and in vivo tests prior to 
first use in humans, followed by clinical patient evaluation to demonstrate safety. There is a large 
literature base focussing on the development of novel materials for mucosal drug delivery. These 
novel materials may not be incorporated into intravaginal products without regulatory approval in 
their own right. When a new drug application is submitted, the presence of novel excipients in the 
medicine must be declared. The safety of these excipients must be supported by appropriate 
toxicological studies and the FDA provides guidance for industry on “Nonclinical Studies for the Safety 
Evaluation of Pharmaceutical Excipients” [118]. This process adds a significant time, cost and risk 
burden for any product development pathway which makes the introduction of novel excipients into 
medicines challenging and unattractive to the pharmaceutical industry. The USP provides additional 
“<1074> excipient biological safety evaluation guidelines” which gives an overview of toxicological 
tests to consider for mucosal drug delivery, but highlights that for regulatory approval, the regulators’ 
specific guidelines must be met. Guidance for industry is available from the FDA for “nonclinical” 
safety studies to precede use of medicines in humans, which aims to revise ICH harmonization of 
recommendations [119]. These guidelines cover a battery of nonclinical tests, such as acute toxicity, 
repeated dose toxicity, local tolerance, genotoxicity and carcinogenicity studies.  
The EMA require local tolerance testing of medicines prior to evaluation in humans (Document: 
EMA/CHMP/SWP/2145/2000). This recommendation requires testing on the site of intended 
application, the vagina, but also those sites that might come into contact through accidental or 
unavoidable exposure, e.g. skin and the glans penis. The EMA require that extensive in vitro evaluation 
of the product’s potential to cause harm be evaluated prior to in vivo studies. The EMA also require 
that the sensitising potential of intravaginal product be evaluated by e.g. guinea pig models. 
The FDA has specific guidance for products intending to act as contraceptives or prevent the 
transmission of STDs [120]. In brief, the FDA recommends that these medicines undergo toxicity 
testing at three dose levels using controls which elicit frank toxicity at the high dose and no toxicity at 
the lowest dose. Pharmacokinetics are required, given the high permeability of the reproductive 
mucosal sites. In addition, it is advised that any product undergo irritation study in rabbits, 
genotoxicity assessment (e.g. AMES testing, in vitro mouse lymphoma tk assay, and mouse 
micronucleus test), reproductive toxicity study, and evaluation of carcinogenicity.  
 
6.2.1 The transfer of drug from the vagina to other sites 
Transfer of drug from vagina to the penis during coitus is possible. For instance, crinone, a 
progesterone gel to treat infertility, contains sorbic acid which may cause irritation or contact 
dermatitis and it is suggested that partners wear a condom during coitus due to potential for irritation 
of the penis [121]. Contraceptive products, such as spermicide gels, are frequently used as an 
alternative to barrier contraception, so exposure of the glans penis to drug is inevitable. Drug transfer 
during coitus has also been investigated for an intravaginal estradiol cream. It was found that men 
absorb vaginal estradiol during intercourse, whereas in women coitus reduced estradiol absorption 
[122]. The authors indicate that frequent exposure may lead to feminizing changes in men. There has 
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also been a clinical trial demonstrating coital transfer of progesterone, used to assist reproduction 
[123]. It was found that unprotected intercourse during usage of an intravaginal progesterone cream 
led to significantly reduced absorption in women, possibly affecting efficacy, and transfer of drug to 
the male partner’s system, potentially causing an adverse reaction e.g. reduced libido. As these 
creams are used to assist reproduction, condom use is not an option to stop transfer. The transfer of 
levonorgestrel, a contraceptive progestogen, from an intravaginal carrageenan gel has also been 
investigated, however in this case there was no significantly reduced absorption, and levonorgestrel 
was only detected in 2 out of 12 male partners [124]. This suggests that the nature of the drug and/or 
dosage form may affect transfer during coitus. Vaginal use of 
sulfathiazole/sulfacetamide/sulfabenzamide cream was reported to be the cause of a partner’s penile 
drug eruption following intercourse [125]. The male partner had a known sensitivity to 
trimethoprim/sulfamethoxazole.   
In addition to drug transfer to a partner, administration of a drug intravaginally can lead to appearance 
of drug in other locations of the body. The transfer of drug from the vagina to the uterus, the “uterine 
first pass effect”, occurs via transfer of drug from vaginal vein to the uterine arterial blood, which also 
allows for transfer to the urethra [126]. Additionally, drug transfer to the rectum is possible. A trial 
studying the pharmacokinetics of a CCR5 inhibitor in macaques found that there was significant 
appearance of drug in the rectal fluid of macaques following intravaginal administration, and vice 
versa [127]. This demonstrates that there is efficient transfer of drug from vagina to rectum. This is 
likely a result of the diffusion of drug across the connecting tissue, though it was also postulated that 
drug could be taken into the uterine artery and then distributed to the rectum via the blood vessels 
of the arteriovenous plexus. 
Systemic absorption of drugs for the treatment of local disease is also possible. For instance, it was 
found that the antibiotic clindamycin had an absolute bioavailability of up to 13 % following 
intravaginal application of a clindamycin cream [128]. Another example is the systemic absorption of 
tioconazole following the use of pessaries to treat vaginal candidiasis [129]. This leads to unnecessary 
exposure of the system to the drug and potential for adverse drug reactions. There are also concerns 
for the use of some intravaginal medicines in pregnant women, where drug may be absorbed into the 
system and act on a developing fetus. There are suggestions, for instance, that intravaginal fluconazole 
medicines be avoided during pregnancy due to the potential for teratogenicity [130]. 
 
6.3 RECENT CLINICAL TRIALS OF INTRAVAGINAL MEDICINES 
The majority of intravaginal formulations would follow the approval pathways for new drug products, 
receive marketing authorisation on those grounds, and thus require clinical trial. In some cases, 
however, intravaginal medicines may follow the processes associated with medical devices. For 
instance, vaginal moisturisers for the treatment of vaginal dryness are classified as Class IIa Medical 
Devices by the UK’s Medicines and Healthcare products Regulatory Agency [131] and thus may be 
produced under responsibility of the manufacturer. For generic intravaginal medicines with systemic 
effect, bioequivalence studies may be used as a surrogate, but for local action therapeutic efficacy 
must still be demonstrated.  This section will focus mainly on those medicines which have failed clinical 
trials, highlighting potential pitfalls, and will also discuss individual trials which have implication for 
formulation design or the future direction of intravaginal drug delivery. 
There have been several clinical trials looking at the efficacy of vaginally administered antiretrovirals 
in the prevention of HIV transmission, with mixed results. One of the first topical intravaginal HIV PrEP 
agents was the non-ionic surfactant nonoxynol-9. This product failed to demonstrate efficacy at phase 
II/III clinical trial spread across Benin, Côte d'lvoire, South Africa and Thailand. It was found that 
nonoxynol-9 use caused adverse toxic events which enhanced HIV infection [132]. The majority of 
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adverse events were related to vaginal mucosa irritation. It was subsequently discovered that 
nonoxynol-9 could promote HIV transmission through interleukin-1-mediated NF-kappaB activation, 
which lead to the immune cell recruitment, which provided host cells for HIV-1 [133]. More promising 
results have been found with tenofovir-containing medicines. Tenofovir is a reverse-transcriptase 
inhibitor, which has been formulated into a gel, with the intention of reducing HIV transmission during 
coitus. The CAPRISA 004 phase IIb clinical trial evaluated the efficacy and the safety of a 1 % tenofovir 
vaginal gel in the prevention of HIV infection in South African women [134]. CAPRISA 004 concluded 
that application of the gel before and after coitus reduced HIV infection by 39 %, and that women who 
used the gel more frequently had a 54 % reduction in HIV transmission. This promising trial was 
expanded in the FACTS001 phase III trial, conducted on 2059 South African women, which failed to 
prove efficacy. It was found that the gel was effective in women who used the gel in >72 % of sex acts, 
however only 20 % of women used it in this manner. This indicates that most women were unable to 
use the gel in a manner that rendered it effective, or simply chose not to adhere to the treatment 
regimen. It has been suggested that poor patient adherence to tenofovir gel medicines is a result of 
messiness and leakage of the medicine, which were found to be disliked features in a sensory study 
[105].  Thus, future medicines which reduce messiness and leakage are highly desirable 
BufferGel (ReProtect Inc, USA) and 0.5% PRO2000 (Endo Pharmaceuticals Solutions Inc., USA), were 
sulphated cellulose products which intended to reduce HIV transmission by buffering and by inhibiting 
viral attachment, respectively. In clinical trials, neither product demonstrated efficacy at preventing 
HIV transmission [135]. An analysis of the users of 0.5% PRO2000 during an earlier phase I clinical trial 
found that 97.2 % of women liked the product, but that 70 % did not like the smell and indicated that 
they would prefer a product that would go unnoticed by men [136]. SAVVY vaginal gel (C31G) was a 
myristamine oxide and cetyl betaine-containing product for HIV PrEP developed by Cellegy 
Pharmaceuticals. The surfactants contained within the gel were intended to disrupt the membrane of 
the HIV pathogen [137]. Phase III clinical trials of SAVVY in Ghana and Nigeria were terminated midway 
due to a lack of evidence for efficacy [138,139]. Several factors may have contributed to the failure of 
the trial [139].  Low HIV incidence was found in the placebo group – it is suggested that those who 
wish to join trials are possibly inclined to safer behaviour. Patient adherence may be low, or over-
reported. Condom-use during the trial confounded findings – the gel was reportedly used alone in 
only 9 % of coital acts. Carraguard is a carrageenan-based product intended for use in PrEP. It was 
found to be safe in phase I and II clinical trials and demonstrated antiviral activity in vitro. However, a 
phase III clinical trial was unable to show that Carraguard reduces the risk of male-to-female 
transmission of HIV. This was put down to poor adherence to the product (it was used in only 42.1 % 
of sexual acts), that the authors attribute to patients forgetting to use the medicines, or running out 
of supply. They also suggested that the control product, a methylcellulose gel, may have been 
imparting a protective effect. The overall challenges with adherence to topical HIV PrEP have been 
reviewed by Gengiah et al [140], who report that for vaginal gels, the biggest issue with adherence 
related to formulation is the “wetness and leakage” of vaginal gels. The authors also highlight issues 
with partners feeling vaginal rings during intercourse, highlighting advantages of gel-based medicines. 
Vivagel® is a dendrimer formulation for the prevention of HIV and treatment of bacterial vaginosis 
developed by Starpharma (Australia). It was fast streamed by the FDA in 2006 for the prevention of 
HIV. Vivagel® has undergone a significant number of clinical trials, but is not yet approved for the 
prevention of HIV. It is, however, marketed in Australia in the form of a condom with Vivagel® 
lubricant, and has approval in the European Union for the treatment and relief of bacterial vaginosis 
[141]. In phase I clinical trials it was found that Vivagel® caused no serious adverse events, but that 
there was a significantly higher incidence of low-grade adverse events in one study [142]; another 
found evidence of mild irritation and inflammation [143]. 
The US-based Contraceptive Research and Development Program’s (CONRAD) “Quatro Study” 
(clinicaltrials.gov identifier: NCT02602366) aims to assess the acceptability and user preference of 
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four different vaginal microbicide products; a rapidly-disintegrating vaginal insert, intravaginal ring, 
film, and gel. The trial aimed to finish in April 2017, and results have not yet been published, but will 
offer an insight to patient preference between dosage forms. 
In situ gelling metronidazole formulations based on poloxamer 407 and F68 have been investigated 
for treatment of bacterial vaginosis in a pilot study by Shabaan et al [144]. It was found that cure rates 
were significantly higher in the in situ gel group compared to a conventional gel (85 v 71 % at week 
one; 80 % v 47.4 % at week four). There was also a lower number of cases of vaginal discharge reported 
in the study. 
Vaginal gels containing lidocaine have been investigated as a method of reducing the pain associated 
with intrauterine device insertion, but clinical trial failed due to lack of efficacy [145]. There did appear 
to be some anaesthetic effect, as the pain associated with placement of a tenaculum (a surgical forcep) 
was reduced in the lidocaine gel group. 
Preterm births are associated with an early shortening of the cervix. Intravaginal progesterone gel 
therapy has been demonstrated to reduce the number of cervical shortening events, and mean cervix 
length, in a large clinical trial of women with a history of preterm birth [146]. This therapy has the 
potential to reduce numbers of prematurely born infants. 
 
8.0 CONCLUSIONS 
 
Vaginal drug delivery offers many opportunities for novel treatments of local disease, and for systemic 
drug delivery. It is, however, a difficult route of administration due to its sensitivity and the difficulty 
in retaining dosage forms. Gel formulations currently in use offer ease-to-use treatments for a variety 
of conditions, and recent advances in the area of pre-exposure HIV prophylaxis has increased interest 
in vaginal delivery. Users of vaginal gels often complain of messiness and leakage, which reduces their 
adherence to a treatment regimen, thus lowering efficacy. Sensory evaluation of vaginal gels is 
therefore crucial before clinical trial takes place, in order to ensure adherence to treatments. Efforts 
to improve the retention of vaginal medicines involves the incorporation of “mucoadhesive” 
excipients or the thickening of gels within the vagina, using pseudoplastic or thixotropic gel systems 
which shear-thin during application, or using thermogelling materials, which increase in viscosity after 
warming in the vagina. Synthetic materials have been created to enhance mucoadhesion and 
retention in the vagina, however these polymers have not yet been approved for use in humans and 
there is a greater need for researchers to consider the toxicity and irritancy of these products during 
their design. In particular, irritation of the vaginal mucosa has been a significant issue in PrEP research, 
enhancing HIV transmission. 
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